Table 2.

Characteristics of the Infants Who Acquired Multiclass Resistance*

Infant with MCR	Mother received sdNVP	Infant regimen for pMTCT	Duration of regimen, days	Age at HIV infection diagnosis	Infant age at the visit where mother first reported HAART usea	Last visit when the mother reported EBF	Last visit when the mother reported MBF	Loss to follow-up due to infant death
1	No	Control	7	14 wk	6 wk	6 mo	18 mo
2	Yes	Control	8	6 wk	6 wk	14 wk	NA	18 mo
3	Yes	Ext NVP	15	In utero	6 wk	14 wk	12 mo
4	Yes	Ext NVP+ZDV	37	In utero	6 wk	14 wk	NA
5	Yes	Control	8	6 wk	9 wk	14 wk	12 mo
6	Yes	Control	8	6 wk	14 wk	6 mo	NA	9 mo
7	Yes	Ext NVP	57	6 wk	14 wk	6 mo	9 mo	12 mo
8	Yes	Ext NVP	14	In utero	14 wk	14 wk	18 mo
9	Yes	Control	8	6 wk	6 mo	6 mo	18 mo
10	Yes	Ext NVP	35	In utero	6 mo	6 mo	18 mo
11	Yes	Ext NVP+ZDV	14	In utero	6 mo	6 mo	9 mo

NOTE. Characteristics of the 11 infants who had multiclass resistance (MCR) are shown. Control, sdNVP plus 1 week of ZDV; Ext NVP, control plus up to 14 weeks of daily NVP; Ext NVP + ZDV, control plus up to 14 weeks of daily NVP and ZDV. sdNVP, single-dose nevirapine; pMTCT, prevention of mother-to-child transmission of HIV; HAART, highly active antiretroviral therapy; EBF, exclusive breastfeeding; MBF, mixed breastfeeding; wk, weeks; mo, months; NA, not available. ^a The actual date of maternal HAART initiation was sometime between this visit and the prior study visit.